Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Anxiety in Glioblastoma Patients
NCT05753007Phase 2Terminated
- Sponsor
- McLean Hospital
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anxiety disorder comparing Cannabidiol (CBD) Solution Plus Standard of Care (SOC) with Placebo (2 arms). Primary endpoints: Beck Anxiety Inventory at 8 weeks and Overall Anxiety Severity and Impairment Scale at 8 weeks. Started Feb 2024; status: terminated.
02
Drugs
cannabidiol
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT05753007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753007.